# A Study of ACE-2494 in Healthy Subjects

> **NCT03478319** · PHASE1 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ACE-2494 or placebo

## Key facts

- **NCT ID:** NCT03478319
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-15
- **Primary completion:** 2019-06-13
- **Final completion:** 2019-06-17
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03478319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03478319, "A Study of ACE-2494 in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03478319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*